Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report

INTRODUCTION: Despite initial benefit, virtually all patients suffering from EGFR-mutant NSCLC experience acquired resistance to tyrosine kinase inhibitors (TKIs), driven by multiple mechanisms. Recent reports have identified oncogenic kinase fusions as off-target resistance mechanisms; however, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Enrico, Diego, Lacroix, Ludovic, Chen, Jeanne, Rouleau, Etienne, Scoazec, Jean-Yves, Loriot, Yohann, Tselikas, Lambros, Jovelet, Cécile, Planchard, David, Gazzah, Anas, Mezquita, Laura, Ngo-Camus, Maud, Michiels, Stefan, Massard, Christophe, Recondo, Gonzalo, Facchinetti, Francesco, Remon, Jordi, Soria, Jean-Charles, André, Fabrice, Vassal, Gilles, Friboulet, Luc, Besse, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474286/
https://www.ncbi.nlm.nih.gov/pubmed/34589930
http://dx.doi.org/10.1016/j.jtocrr.2020.100023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474286/
https://www.ncbi.nlm.nih.gov/pubmed/34589930
http://dx.doi.org/10.1016/j.jtocrr.2020.100023

Ejemplares similares